Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025)
Neuphoria Therapeutics (NEUP) reported Research & Development of $697723.0 for Q4 2025, down 59.83% year-over-year from $1.7 million in Q4 2024, and down 81.57% on a QoQ basis from $3.8 million in Q3 2025.
Neuphoria Therapeutics (NEUP) has 3 years of Research & Development data on file, last reported at $697723.0 in Q4 2025.
- Quarterly Research & Development fell 59.83% year-over-year to $697723.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.9 million (up 24.18% YoY) and the FY2025 annual result came in at $9.0 million, down 4.38% from the prior year.
- Research & Development slipped to $697723.0 in Q4 2025 per NEUP's latest filing, from $3.8 million in the prior quarter.
- Across five years, Research & Development topped out at $3.8 million in Q3 2025 and bottomed at $697723.0 in Q4 2025.
- The 3-year median for Research & Development is $2.0 million (2023), against an average of $2.3 million.
- Peak annual rise in Research & Development reached 99.15% in 2025, while the deepest fall reached 59.83% in 2025.
- Tracing NEUP's Research & Development over 3 years: stood at $2.0 million in 2023, then slipped by 14.64% to $1.7 million in 2024, then sank by 59.83% to $697723.0 in 2025.
- Per Business Quant, the three latest NEUP Research & Development figures stand at $697723.0 (Q4 2025), $3.8 million (Q3 2025), and $3.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 697,723.00 |
| Sep 30, 2025 | 3.79 Mn |
| Jun 30, 2025 | 3.75 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 3.09 Mn |